MedInCell Stock Drops 2.23% to €26.34 but Maintains a +69% Yearly Gain
The Montpellier-based biotech's stock falls 2.23% to €26.34 at midday in a declining Paris market. The SBF 120 is down 0.44% and the CAC 40 loses 0.49% during the session. However, the stock still holds a gain of over 69% for the year.
A Retreat Bringing the Stock Back to Its 20-Day Moving Average
MedInCell stock erases part of the rebound that began in early May. Over the week, the stock has dropped 6.2%, after reaching €28.14 on May 15. Nonetheless, the price remains above its 20-day moving average (€25.71), with a limited gap of 2.45%.
The resistance at €28.72, identified in previous sessions and already mentioned in a brief published on May 20, has not been breached. The RSI at 58 remains in the neutral zone, with no overbought signal. The MACD, with its histogram slightly in negative territory (-0.03), indicates a waning of the short-term bullish momentum.
The three-month performance stands at +10.3%, and the one-year performance at +69.06%. Thus, the stock maintains a fundamentally positive trajectory, despite recent fluctuations.
Slight Increase in Net Short Positions, at 2.07% of Capital
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
According to reviewed declarations, three funds together hold a cumulative net short position of 2.07% of MedInCell's capital. This level has risen by 0.11 points over thirty days, from 1.96% a month ago.
This change does not indicate a massive movement of distrust, but it shows that some institutional investors remain positioned against the stock, or are seeking to hedge exposure. This point should be monitored, though not interpreted in isolation, in a context where the biotech has already experienced several phases of volatility since the beginning of the year.
The company's headquarters are located in Jacou, in the Hérault department, and the chairman of the board is Philippe André Guy. The next technical reference to watch remains the €28.72 resistance, which a return of buyers should surpass to reignite the upward trend.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
